Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
Kaufman GP, et al. Blood 2017. Among authors: Liedtke M.
PMID 28615223
The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achieve a complete response (CR) to standard light chain suppressive chemotherapy, and almost all patients eventually experience hematologic relapse and progression of organ involvement. ...
The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achieve a complete response (CR) to standard light chain suppressive chemotherapy, and almost all patients eventually experience hematologic relapse and progression of organ involvement. ...